All T-ALL cell lines have an IC50 value < 1 μM following treatment with either AKTi or mTORC1/2i, whereas there was a varying degree of sensitivity to the PI3K inhibitors. The gene discussed is PIK3CB; the disease is acute lymphoblastic leukemia.